pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Gene Therapy (AAV) · news · pharmadog
← back to Gene Therapy (AAV)
News · Gene Therapy (AAV)
527
stories
10h
STAT+: 7 burning questions about the FDA’s post-Overton future
stat
14h
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
biopharma dive
15h
STAT+: FDA discloses reasons for rejecting Summit drug
stat
1d
5 acquisitions that forced Big Pharmas to co-parent
biospace
1d
STAT+: Flagship opens biotech-creation outpost in the U.K.
stat
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
1d
Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
biospace
1d
NIH’s infectious disease unit has a new head at last
stat
1d
Genetix’s genetic medicines are officially profitable, with $327M in sales YTD
biospace
1d
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
biospace
1d
Marrow sets out to challenge genetic medicines for severe blood diseases
biopharma dive
1d
STAT+: With $173 million, new startup takes aim at sickle cell
stat
1d
Flavored nicotine tablets, the tobacco industry’s latest product, worry public health advocates
stat
1d
STAT+: After death in gene therapy trial for a brain disease, progress is reported
stat
2d
STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC
stat
2d
J&J bets $2.2B on Ollin’s vision loss drug
biopharma dive
2d
STAT+: Biotech’s rebound isn’t lifting all boats equally
stat
2d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
2d
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
biospace
2d
STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
stat
2d
STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
stat
2d
STAT+: Venture capitalist John Doerr says AI company, named for his late brother, could help fix primary care
stat
2d
STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
stat
2d
Seawolf launches with $100M to make non-viral gene therapies
endpoints
2d
Big-name investors pour $100M into DNA therapeutics developer Seawolf
biopharma dive
3d
Emerging biotech hubs step up as innovation economics evolve
biospace
3d
Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
biospace
3d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
5d
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
biospace
6d
Cellectis will shed 70% of workforce as part of in vivo pivot
fiercebiotech
← prev
page 1 of 18
next →